Meeting Banner
Abstract #0987

Prospective multi-institutional validation of  IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (MULTI-IMPROD trial)

Ivan Jambor1,2, Janne Verho1, Otto Ettala3, Juha Knaapila3, Pekka Taimen1, Kari Syvänen3, Aida Kiviniemi1, Esa Kähkönen3, Ileana Montoya Perez1, Marjo Seppänen4, Antti Rannikko5, Outi Oksanen5, Jarno Riikonen6, Sanna-Mari Vimpeli6, Tommi Kauko3, Harri Merisaari1, Tarja Lamminen3, Markku Kallajoki3, Tuomas Mirtti7, Jani Saunavaara3, Hannu Aronen1, and Peter J Boström3

1University of Turku, Turku, Finland, 2Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3Turku University Hospital, Turku, Finland, 4Satakunta Central Hospital, Pori, Finland, 5Helsinki University Hospital, Helsinki, Finland, 6Tampere University Hospital, Tampere, Finland, 7University of Helsinki, Helsinki, Finland

In this prospective multicenter trial, a prior developed unique MRI acquisition and reporting protocol, IMPROD bpMRI (NCT01864135), enabled the detection of 97% (143/146) of men with Gleason score ≥3+4. IMPROD bpMRI consists of T2-weighted imaging and three separate diffusion weighted imaging acquisitions with acquisition time <15 minutes. IMPROD bpMRI appears to be a powerful tool for improved prostate cancer risk stratification in men with a clinical suspicion of prostate cancer based on elevated PSA and/or digital rectal examination. Public access to all data is provided at the following addresses: http://petiv.utu.fi/improd and http://petiv.utu.fi/multiimprod

This abstract and the presentation materials are available to members only; a login is required.

Join Here